CClinicalTrials.gg
CompletedNCT04888767ITHIUpdated Sep 15, 2023

Safety and Feasibility of High-intensity Interval Training Program in CF Patients

An interventional study of Interval Training Hight Intensity Program in Cystic Fibrosis, sponsored by Fondation Ildys. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Fondation Ildys · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study compare an usual training program (in continuous endurance) with an ITHI program over a period of 3 weeks, in France. The aim is to evaluate the safety and feasibility of this type of program in CF adults, and also more specifically, in subgroups:

patients divided according to the severity of their FEV1 ; patients treated with modulating CFTR canal therapy ; diabetic patients on insulin ; undernourished patients.

Read the detailed description

Objectives Studies have shown good tolerance of High Intensity Interval Training (ITHI) in healthy people or in COPD with similar results obtained with continuous training regimen, but with less shortness of breath and muscle fatigue, greater pleasure and a positive impact on glycemia. Research in CF is still scarce.

We propose to compare our usual training program (in continuous endurance) with an ITHI program over a period of 3 weeks, corresponding to the length of the rehabilitation stay in France. Our aim is to evaluate the safety and feasibility of this type of program in CF adults, and also more specifically, in subgroups:

  • patients divided according to the severity of their FEV1
  • patients treated with modulating CFTR canal therapy
  • diabetic patients on insulin
  • undernourished patients (BMI ≤ 18.5)

Methodology

  • Bicentric (Roscoff-Giens); prospective; opened; randomized; controlled
  • Rehabilitation stay in hospitalization with 18 days of training, on an ergometer, supervised by an APA teacher or a physiotherapist

    • Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold
    • Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible
  • Distribution of the 100 patients included in a 1: 1 ratio
  • Examinations / Questionnaires in current practice: medical consultation; quality of life (CFQ-R); anxiety-depression (HAD); "Starfish" (Feelings linked to physical activity) ; blood sugar (Freestyle); impedance measurement; respiratory capacity measurement ; Voluntary Driving Force; walk test (TM6); dyspnea scale (Borg)
  • Study-specific measures: MDP (Multidimensional Profile of Dyspnea) and PACES (Physical Activity Enjoyment Scale) scales

Expected results

Through this pilot study we are expecting to answer several questions:

  • are the safety and tolerance of an ITHI program at least equal if not better than that of a "classic" training?
  • what about the most severe patients?
  • could patients on modulator have ITHI training (treatment likely to increase creatine kinase - muscle enzyme -)?
  • are diabetic patients more at risk of hypoglycaemia during an ITHI compared to traditional training?
  • could undernourished patients participate in ITHI regimen?

Perspective If ITHI appears to be safe and well tolerated, it could be integrated into "classic" rehabilitation programs and represent an interesting alternative, depending on the profile of each patient. The effectiveness of the ITHI program will also be discussed by evaluating several parameters, including 6mn walking distance test (6MWD). The emerging trends would allow some recommendations and more in-depth studies.

02

Conditions studied

  • Cystic Fibrosis

Keywords

  • Cystic fibrosis
  • Respiratory rehabilitation program
  • Physical activity
  • High intensity interval training
  • Quality of life
03

In context

Cystic Fibrosis

1,581 studies on the registry are indexed under Cystic Fibrosis; 190 are open to participants now.

This study's enrollment of 62 is above the median of 36 across 1,034 interventional studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

Fondation Ildys is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • men and women aged over 18 years of age on the date of informed consent
  • diagnosed CF patients
  • not transplanted and not on the transplant waiting list
  • able to participate in the proposed training programs (especially without cardiac contraindication)
  • able to understand and respect the protocol and its requirement
  • who signed the consent prior to any other procedure protocol

Exclusion criteria

Exclusion Criteria:

  • major patients under guardianship / curatorship / legal protection
  • pregnant patients
  • dialysis patients
  • patients with a severe exacerbation at the time of inclusion
  • patients for whom a new modulating treatment (eg.: Kaftrio®, Kalydeco®, Symkevi®, etc.) has been implemented in the 4 weeks preceding inclusion
  • patients with pulmonary arterial hypertension (≥ 25 mmHg)
  • patients unable to complete the entire program
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • No intervention
    Control group

    Patients benefiting from the usual re-training sessions

  • Experimental
    ITHI Group

    Patients benefiting from ITHI re-training sessions

    Other: Interval Training Hight Intensity Program

Interventions

  • OtherInterval Training Hight Intensity Program

    * Rehabilitation stay in hospitalization with 18 days of training sessions * Training on an ergometer * Sessions supervised by an Adapted Physical Activities (APA) teacher or a physiotherapist * Control group: 5 times / week; continuous work 20 to 30 min; around the 1st aerobic ventilation threshold * Intervention group: 2 times / week: maintenance sessions + 3 times / week: IHTI sessions - alternating 30s work / 30s rest repeated 6 times; at 60% of the maximum heart rate at the 1st session then increase as fast and large as possible

06

What researchers measure

Primary outcomes

  1. Feasability evaluation

    Proportion of sessions carried out according to the planned program (and, in parallel, number and reasons for stopping sessions or the program)

    Time frame: Continuous measurement over the entire stay (Day 1 to Day 18)

  2. Tolerance evaluation

    Scores on the Borg scale (physical activity dyspnea and muscle fatigue) : 0 to 10 - Higher score = worse outcome

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

Secondary outcomes

  1. Cystic Fibrosis Questionnaire Revised (CFQR)

    Scores on CFQR (assessment of quality of life) : 0 to 100 - Higher score = better outcome

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

  2. Hospital Anxiety and Depression scale (HAD)

    Scores on HAD : 2 scores (1 for anxiety and 1 for depression) - 0 to 21 - Higher score = worse outcome

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

  3. Starfish

    Scores on the "starfish": assesment of the feelings about physical activity with an educational diagram - 12 "branches" = 12 sub-scores - 0 to 12 - Higher score = better outcome

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

  4. Anthropometry

    Weight (Kg) and height (cm) will be combined to report BMI in kg/m2

    Time frame: Change from baseline (Day 1) at 3 weeks (Day 18)

  5. Continuous blood sugar levels

    Evaluation of the glucose levels (average, minimum, maximum)

    Time frame: Continuous measurement over the entire stay (Day 1 to Day 18)

  6. Ponctual blood sugar levels

    Blood glucose assessment during re-training sessions (at the start; during; at the end; after recovery)

    Time frame: Measurement at each sessions from Day 2 to Day 18

  7. Impedance

    Bioelectrical impedance analysis of body composition

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

  8. Spirometry

    Respiratory capacity assessment : forced expiratory volume in 1 second (FEV1)

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

  9. Maximal Voluntary force : Strength

    Best measurement, in Newton, of thigh quadriceps strength after 6 evaluations (3 with the left thigh and 3 with the right thigh)

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

  10. Maximal Voluntary force : endurance

    Best measurement, in second, of thigh quadriceps strength after 2 evaluations (13 with the left thigh and 1 with the right thigh)

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

  11. 6MWT

    Measurement of the distance traveled during the six minutes walk test (6MWT) and of several related parameters (dyspnea, oxygen saturation, heart rate - at the start, at the finish, after rest)

    Time frame: Change from baseline (Day 12) at 3 weeks (Day 18)

  12. Multidimensional dyspnea profile scale (MDP)

    Scores on the MDP : assessment of discomfort (0 to 10), sensory component (0 to 50) and affective component (0 to 50) of breathlessness -\> 3 sub-scores - Higher score = worse outcome

    Time frame: Change from baseline (Day 2) at 3 weeks (Day 18)

  13. Physical Activity Enjoyment Scale (PACES)

    Score on the PACES : assessment of global satisfaction felt during re-training sessions - 10 to 70 - Higher score = better outcome

    Time frame: Measurement at the end of the stay (Day 18)

07

Study locations

2 sites
  • CF Center - Fondation Ildys Site de Perharidy
    Roscoff, Finistère 29684, France
  • CF Center of Giens - Hospices Civils de Lyon Hôpital Renée Sabran
    Giens, Hyères 83400, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04888767
Lead sponsor
Fondation Ildys
Collaborators
Lille Catholic University
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Sep 1, 2021
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Last update
Sep 15, 2023

Study contacts

Sophie Ramel, MD
principal investigator · Fondation Ildys

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion